Ng Kei Shing, Lian Jie, Huang Fan, Yu Yan, Vardhanabhuti Varut
Snowhill Science Limited, Hong Kong, Hong Kong SAR, China.
Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Front Physiol. 2024 Dec 5;15:1465168. doi: 10.3389/fphys.2024.1465168. eCollection 2024.
This study aimed to determine the associations between different intensities of moderate to vigorous physical activity (MVPA) and the incidence of chronic diseases, and to assess the risk levels associated with these activities over time.
A prospective cohort study (UK Biobank Activity Project) with data collected between June 2013 and December 2015 included 59,896 adults (mean age = 59.68; male = 38.03%) free from chronic diseases. Participants were categorized into tertiles based on their weekly MVPA: lowest (<224 min for males, <143 min for females), medium (224-444 min for males, 143-308 min for females), and highest (≥444 min for males, ≥308 min for females), stratified by gender. The mean onset of chronic disease symptoms occurred at 3.57 years, with participants followed up during this period. Wearable accelerometry data were used to quantify MVPA levels.
Lowest tertile of MVPA were significantly correlated with increased risks of chronic disease (24%-110% increased risk) based on odds ratios (ORs), with dose-response relationship observed. In males with the lowest tertile of MVPA, significant associations were identified with type 2 diabetes mellitus (T2DM) (OR = 1.90; CI: 1.44-2.51), neurodegenerative disease (OR = 1.80; CI: 1.19-2.71), metabolic syndrome (OR = 1.34; CI: 1.18-1.53), hypertension (OR = 1.27; CI: 1.12-1.44), and atherosclerotic cardiovascular disease (ASCVD) (OR = 1.24; CI: 1.03-1.49). In females, the lowest tertile of MVPA levels were associated with increased risks of neurodegenerative disease (OR = 2.10; CI: 1.36-3.24), T2DM (OR = 1.88; CI: 1.37-2.58), cerebrovascular disease (OR = 1.61; CI: 1.12-2.29), ASCVD (OR = 1.58; CI: 1.23-2.03), metabolic syndrome (OR = 1.49; CI: 1.32-1.69), and hypertension (OR = 1.44; CI: 1.29-1.61). Longitudinally, the lowest tertile of MVPA in males showed elevated risks for neurodegenerative disease (HR = 2.13; CI: 1.24-3.66), T2DM (HR = 1.83; CI: 1.30-2.57), hypertension (HR = 1.33; CI: 1.15-1.53), metabolic syndrome (HR = 1.32; CI: 1.14-1.54), and ASCVD (HR = 1.29; CI: 1.03-1.61). In females, the lowest tertile of MVPA was associated with similar risks for ASCVD (HR = 1.59; CI: 1.16-2.20), T2DM (HR = 1.57; CI: 1.08-2.29), hypertension (HR = 1.53; CI: 1.34-1.74), and metabolic syndrome (HR = 1.50; CI: 1.29-1.73).
Using wearable accelerometry data, this study demonstrated the quantifiable risks of chronic diseases and their development, highlighting the importance of MVPA.
本研究旨在确定不同强度的中等至剧烈身体活动（MVPA）与慢性病发病率之间的关联，并评估这些活动随时间推移相关的风险水平。
一项前瞻性队列研究（英国生物银行活动项目），收集了2013年6月至2015年12月期间的数据，纳入了59896名无慢性病的成年人（平均年龄=59.68岁；男性=38.03%）。参与者根据其每周的MVPA被分为三分位数：最低（男性<224分钟，女性<143分钟）、中等（男性224 - 444分钟，女性143 - 308分钟）和最高（男性≥444分钟，女性≥308分钟），并按性别分层。慢性病症状的平均发病时间为3.57年，在此期间对参与者进行随访。使用可穿戴式加速度计数据来量化MVPA水平。
基于优势比（OR），MVPA最低三分位数与慢性病风险增加显著相关（风险增加24% - 110%），观察到剂量反应关系。在MVPA最低三分位数的男性中，发现与2型糖尿病（T2DM）（OR = 1.90；CI：1.44 - 2.51）、神经退行性疾病（OR = 1.80；CI：1.19 - 2.71）、代谢综合征（OR = 1.34；CI：1.18 - 1.53）、高血压（OR = 1.27；CI：1.12 - 1.44）和动脉粥样硬化性心血管疾病（ASCVD）（OR = 1.24；CI：1.03 - 1.49）有显著关联。在女性中，MVPA水平最低三分位数与神经退行性疾病（OR = 2.10；CI：1.36 - 3.24）、T2DM（OR = 1.88；CI：1.37 - 2.58）、脑血管疾病（OR = 1.61；CI：1.12 - 2.29）、ASCVD（OR = 1.58；CI：1.23 - 2.03）、代谢综合征（OR = 1.49；CI：1.32 - 1.69）和高血压（OR = 1.44；CI：1.29 - 1.61）的风险增加相关。纵向来看，男性MVPA最低三分位数显示神经退行性疾病（HR = 2.13；CI：1.24 - 一、3.66）、T2DM（HR = 1.83；CI：1.30 - 2.57）、高血压（HR = 1.33；CI：1.15 - 1.53）、代谢综合征（HR = 1.32；CI：1.14 - 1.54）和ASCVD（HR = 1.29；CI：1.03 - 1.61）的风险升高。在女性中，MVPA最低三分位数与ASCVD（HR = 1.59；CI：1.16 - 2.20）、T2DM（HR = 1.57；CI：1.08 - 2.29）、高血压（HR = 1.53；CI：1.34 - 1.74）和代谢综合征（HR = 1.50；CI：1.29 - 1.73）的风险相似。
本研究使用可穿戴式加速度计数据证明了慢性病及其发展的可量化风险，突出了MVPA的重要性。
